Susan Benton - 03 Jan 2022 Form 4 Insider Report for Ocuphire Pharma, Inc. (IRD)

Role: Director
Signature: s/ Jeffrey Kuras, by Power of Attorney
Issuer symbol: IRD
Transactions as of: 03 Jan 2022
Net transactions value: $0
Form type: 4
Filing time: 05 Jan 2022, 15:01:23 UTC
Previous filing: 04 Oct 2021
Next filing: 05 Apr 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	OCUP	Common Stock	Award		+2,949	+11%		29,060	03 Jan 2022	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Reporting Person was granted common stock in lieu of cash for Q4 2021 Board services. The number of shares of Common Stock having an aggregate Fair Market Value equal to the aggregate amount of the Retainers for such fiscal quarter, determined by dividing (A) the aggregate amount of the Retainers by (B) the Fair Market Value of the Common Stock on last day of the fiscal quarter (rounded down to the nearest whole share). The Fair Market Value was $3.73 per share, the closing price of the Company's stock on December 31, 2021.

Content

The Reporting Person was granted common stock in lieu of cash for Q4 2021 Board services. The number of shares of Common Stock having an aggregate Fair Market Value equal to the aggregate amount of the Retainers for such fiscal quarter, determined by dividing (A) the aggregate amount of the Retainers by (B) the Fair Market Value of the Common Stock on last day of the fiscal quarter (rounded down to the nearest whole share). The Fair Market Value was $3.73 per share, the closing price of the Company's stock on December 31, 2021.